PD company Prevail launches

RegenxBio Inc. (NASDAQ:RGNX), OrbiMed and The Silverstein Foundation for Parkinson’s with GBA launched Prevail Therapeutics Inc. (New York, N.Y.) to develop biologics to treat Parkinson's disease and other neurodegenerative disorders.

Prevail launches under a deal with RegenxBio, in which the newco gained exclusive, worldwide rights to develop and commercialize gene therapies utilizing RegenxBio's NAV AAV9 vector to treat PD and neurodegenerative diseases...